LEXINGTON, Mass., Aug. 13 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals, Inc.
The '978 patent covers the Company's approved product, SANCTURA XR(TM), a once-a-day formulation of trospium chloride which is indicated for the treatment of symptoms of an overactive bladder. Based on calculations made by the United States Patent and Trademark Office, the term of the '978 patent is twenty years plus 89 days from its filing date of November 4, 2004, or February 1, 2025.
In September 2007, the Company entered into an agreement with Allergan, Inc. by which the Company granted Allergan an exclusive sublicense to market SANCTURA XR in the United States. Allergan and Indevus launched SANCTURA XR in the U.S. in January 2008. Indevus licensed to Rottapharm Madaus Group the right to market SANCTURA XR in certain territories outside the U.S., except in Canada, Japan, Korea and China, where the Company and Rottapharm Madaus have joint rights. In May 2008, Indevus and Rottapharm Madaus licensed rights to market SANCTURA XR in Canada to Allergan.
Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company
engaged in the acquisition, development and commercialization of products
to treat conditions in urology and endocrinology. The Company's approved
products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder,
VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central
precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The
|SOURCE Indevus Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved